Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT00865969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

129

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: Belinostat

Sponsor

Spectrum Pharmaceuticals, Inc

Collaborators

[object Object]